Treos Bio to Present New Colorectal Cancer Immunotherapy Data at 2024 ASCO Meeting

LONDON and BOSTON, May 08, 2024 – Treos Bio, a clinical-stage biotechnology firm leveraging data science and proprietary biomarkers to create precision peptide immunotherapies, announced that researchers will unveil new findings from a phase 2 trial of its primary product candidate, PolyPEPI1018. This product, combined with Roche’s PD-L1 inhibitor atezolizumab, is being tested on patients with advanced-stage microsatellite stable metastatic colorectal cancer (MSS mCRC) at the 2024 ASCO Annual Meeting.

According to the World Health Organization, colorectal cancer (CRC) is the third most prevalent cancer globally and the second leading cause of cancer-related mortalities. In the United States alone, the National Cancer Institute reports approximately 1.4 million individuals are living with CRC. Treatments for CRC typically include surgery and chemotherapy in the early stages, while advanced stages often involve chemotherapy, biologics, and targeted therapies. Notably, around 85 percent of all CRC cases are MSS, and this category includes nearly all instances of metastatic CRC. Unfortunately, current immunotherapies do not benefit patients with MSS CRC.

Treos Bio's leading candidate, PolyPEPI1018, is an off-the-shelf immunotherapy under development to treat metastatic colorectal cancer. This treatment has been co-developed with a candidate companion diagnostic. PolyPEPI1018 is being investigated as a first-line maintenance therapy and a third-line treatment. The companion diagnostic utilizes Treos’ proprietary PASCal computational tool to pinpoint Personal EPItopes (PEPIs) that can potentially trigger antigen-specific T Cell responses in patients.

At the ASCO Annual Meeting, researchers will present a poster featuring new data from the OBERTO 301 trial. This multicenter, open-label, phase 2 study evaluates the combination of PolyPEPI1018 and atezolizumab in patients with MSS mCRC who have not responded to two or three previous treatment regimens. The study’s primary endpoint is the incidence and severity of treatment-related adverse events. Secondary endpoints include objective response rate, duration of response, progression-free survival, and overall survival.

Dr. Christopher C. Gallen, CEO of Treos Bio, expressed optimism regarding the results. He highlighted the consistent outcomes observed across three clinical trials in MSS metastatic colorectal cancer in various settings and noted PolyPEPI1018's unique capability to convert 'cold' tumors into 'hot' tumors.

About Treos Bio Limited:
Treos Bio focuses on developing precision peptide cancer immunotherapies combined with innovative biomarkers using proprietary computational data science. Their approach integrates HLA genetics, tumor profiles, and clinical outcomes from thousands of real-world subjects. Treos has conducted three clinical trials in the United States and the European Union for PolyPEPI1018, an off-the-shelf immunotherapy for treating metastatic colorectal cancer. Additionally, Treos has completed preclinical development of other off-the-shelf immunotherapies for ovarian, breast, bladder, gastric, lung cancers, and melanoma. The company is also working on personalized off-the-shelf immunotherapies tailored to an individual patient's HLA genotype for various solid tumors. Treos Bio has secured $45 million in funding to date.

For further details, please visit www.treosbio.com.